Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have earned an average rating of "Moderate Buy" from the six research firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $4.50.

Several equities analysts have commented on the stock. Barclays decreased their target price on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. Wall Street Zen downgraded shares of Sangamo Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, May 30th. Finally, HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, June 24th.

Institutional Trading of Sangamo Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Golden State Equity Partners lifted its position in Sangamo Therapeutics by 5.4% during the second quarter. Golden State Equity Partners now owns 391,943 shares of the biopharmaceutical company's stock worth $212,000 after buying an additional 20,000 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Sangamo Therapeutics by 30.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 90,550 shares of the biopharmaceutical company's stock valued at $48,000 after purchasing an additional 21,300 shares during the period. Wealth Management Associates Inc. raised its position in Sangamo Therapeutics by 213.7% in the first quarter. Wealth Management Associates Inc. now owns 228,400 shares of the biopharmaceutical company's stock valued at $150,000 after purchasing an additional 155,600 shares during the period. Jacobs Levy Equity Management Inc. raised its position in Sangamo Therapeutics by 74.8% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,297,785 shares of the biopharmaceutical company's stock valued at $851,000 after purchasing an additional 555,323 shares during the period. Finally, Caption Management LLC purchased a new stake in Sangamo Therapeutics in the first quarter valued at $37,000. 56.93% of the stock is owned by institutional investors and hedge funds.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics stock traded down $0.01 during trading hours on Friday, hitting $0.48. 5,227,879 shares of the stock were exchanged, compared to its average volume of 9,118,241. The stock has a market capitalization of $111.87 million, a P/E ratio of -1.23 and a beta of 1.23. Sangamo Therapeutics has a 12 month low of $0.39 and a 12 month high of $3.18. The business's 50-day moving average is $0.50 and its two-hundred day moving average is $0.79.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The firm had revenue of $6.44 million during the quarter, compared to analyst estimates of $7.90 million. Sangamo Therapeutics had a negative return on equity of 345.98% and a negative net margin of 124.61%. On average, equities analysts predict that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.